January 9, 2013
Many investors remember that legendary day in September when shares of then little-known biotech Sarepta (NASDAQ: SRPT ) climbed almost 200% in a single day. The promise behind the company's Duchenne muscular dystrophy drug eteplirsen has generated massive interest in the stock and might have some investors thinking that this is a prime buyout target for big pharma players searching for lucrative drugs.
But wait -- is Sarepta actually looking for an acquirer?
In this video, health care analyst Max Macaluso weighs in on the debate and gives his opinion on whether this fledgling biotech will be acquired.
What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.